Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of vancomycin + piperacillin/tazobactam vs vancomycin + meropenem in suspected central line-associated bloodstream infection in non-critically ill hemodialysis patients
TCTR20240917008Phase 3Unknown
- Sponsor
- Chiang Mai University
- Start
- Oct 2024
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of vancomycin, piperacillin + tazobactam, meropenem in central line-associated bloodstream infection (CLABSI), sponsored by Chiang Mai University. Status: unknown.
02
Drugs
vancomycinpiperacillin + tazobactammeropenem
03
Conditions
central line-associated bloodstream infection (CLABSI)
Beyond the preview
Go deeper on TCTR20240917008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20240917008.